دورية أكاديمية
Clinical impact of an integrated e-health system for diabetes self-management support and shared decision making (POWER2DM): a randomised controlled trial
| العنوان: | Clinical impact of an integrated e-health system for diabetes self-management support and shared decision making (POWER2DM): a randomised controlled trial |
|---|---|
| المؤلفون: | Ruissen, M.M., Torres-Peña, J.D., Uitbeijerse, B.S., Larriva, A.P.A. de, Huisman, S.D., Namli, T., Salzsieder, E., Vogt, L., Ploessnig, M., Putte, B. van der, Merle, A., Serra, G., Rodríguez, G., Graaf, A.A. de, Koning, E.J.P. de, Delgado-Lista, J., Sont, J.K., POWER2DM Consortium |
| المصدر: | Diabetologia |
| سنة النشر: | 2023 |
| المجموعة: | Leiden Repository (Leiden University) |
| مصطلحات موضوعية: | Diabetes, e-health, Glycaemic control, m-health, Quality of life, RCT, Self-management, Shared decision making |
| الوصف: | Aims/hypothesis There is a lack of e-health systems that integrate the complex variety of aspects relevant for diabetes self-management. We developed and field-tested an e-health system (POWER2DM) that integrates medical, psychological and behavioural aspects and connected wearables to support patients and healthcare professionals in shared decision making and diabetes self-management.Methods Participants with type 1 or type 2 diabetes (aged >18 years) from hospital outpatient diabetes clinics in the Netherlands and Spain were randomised using randomisation software to POWER2DM or usual care for 37 weeks. This RCT assessed the change in HbA(1c) between the POWER2DM and usual care groups at the end of the study (37 weeks) as a primary outcome measure. Participants and clinicians were not blinded to the intervention. Changes in quality of life (QoL) (WHO-5 Well-Being Index [WHO-5]), diabetes self-management (Diabetes Self-Management Questionnaire - Revised [DSMQ-R]), glycaemic profiles from continuous glucose monitoring devices, awareness of hypoglycaemia (Clarke hypoglycaemia unawareness instrument), incidence of hypoglycaemic episodes and technology acceptance were secondary outcome measures. Additionally, sub-analyses were performed for participants with type 1 and type 2 diabetes separately.Results A total of 226 participants participated in the trial (108 with type 1 diabetes; 118 with type 2 diabetes). In the POWER2DM group (n=111), HbA(1c) decreased from 60.6 +/- 14.7 mmol/mol (7.7 +/- 1.3%) to 56.7 +/- 12.1 mmol/mol (7.3 +/- 1.1%) (means +/- SD, p<0.001), compared with no change in the usual care group (n=115) (baseline: 61.7 +/- 13.7 mmol/mol, 7.8 +/- 1.3%; end of study: 61.0 +/- 12.4 mmol/mol, 7.7 +/- 1.1%; p=0.19) (between-group difference 0.24%, p=0.008). In the sub-analyses in the POWER2DM group, HbA(1c) in participants with type 2 diabetes decreased from 62.3 +/- 17.3 mmol/mol (7.9 +/- 1.6%) to 54.3 +/- 11.1 mmol/mol (7.1 +/- 1.0%) (p<0.001) compared with no change in HbA(1c) in participants ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://link.springer.com/article/10.1007/s00125-023-06006-2Test; lumc-id: 185746936; https://hdl.handle.net/1887/3720839Test |
| DOI: | 10.1007/s00125-023-06006-2 |
| الإتاحة: | https://doi.org/10.1007/s00125-023-06006-2Test https://hdl.handle.net/1887/3720839Test |
| رقم الانضمام: | edsbas.E0D8466E |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s00125-023-06006-2 |
|---|